ERAS — Erasca, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1761918 ·
Last close
$14.25
Market Cap
$4.98B
52W High
$24.28
52W Low
$1.79
ADV30
4,289,847
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -47,619,000 | -44,079,000 | 435,054,000 | 42,542,000 | 73,185,000 |
| Mar 2026 | 0 | — | -37,911,000 | -183,440,000 | 461,234,000 | 47,256,000 | 67,706,000 |
| Dec 2025 | 0 | — | -32,604,000 | -29,092,000 | 396,154,000 | 73,805,000 | 70,983,000 |
| Sep 2025 | 0 | — | -32,546,000 | -30,612,000 | 420,401,000 | 70,230,000 | 72,515,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-91,283,000
Investing CF
$-177,670,000
Financing CF
$245,727,000
CapEx
$-159,581,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.93
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,075,649,000
Inventory
—
Receivables
—
ST Investments
$196,532,000
EBIT TTM
$-133,686,000
Pretax Income TTM
$-277,020,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -131,405,000 | -124,546,000 | 396,154,000 | 70,983,000 | 325,171,000 | -95,455,000 |
| Dec 2024 | 0 | -157,087,000 | -161,650,000 | 502,526,000 | 79,027,000 | 423,499,000 | -109,417,000 |
| Dec 2023 | 0 | -141,525,000 | -125,042,000 | 395,297,000 | 78,611,000 | 316,686,000 | -101,217,000 |
| Dec 2022 | 0 | -145,450,000 | -242,805,000 | 514,909,000 | 103,056,000 | 411,853,000 | -103,264,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.62
Max Pain — expiry 2026-10-16
max pain strike: $15.00 · spot: $14.26 · call oi: 21,283 · put oi: 5,298
Expected Move to 2026-10-16:
±$2.58
(18.06%) —
implied range
$11.69 –
$16.84
· ATM straddle on $15.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DNTH | Dianthus Therapeutics, Inc. /DE/ | $4.95B | $88.55 | — |
| MANE | Veradermics, Inc | $4.87B | $116.57 | — |
| PTCT | PTC THERAPEUTICS, INC. | $5.23B | $62.67 | — |
| ORKA | Oruka Therapeutics, Inc. | $5.59B | $84.46 | — |
| TVTX | Travere Therapeutics, Inc. | $5.60B | $59.44 | — |
News headlines (Yahoo Finance, 1h cache)
Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
2026-09-16 12:30 · Yahoo
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
2026-09-10 12:00 · Yahoo
Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
2026-09-08 11:00 · Yahoo
FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage
2026-09-04 18:40 · Yahoo
Erasca Reports Second Quarter 2026 Business Updates and Financial Results
2026-08-11 20:01 · Yahoo
Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-10 20:01 · Yahoo
Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns
2026-07-16 03:24 · Yahoo
Erasca (ERAS) Trial Update Draws Fresh Focus, Is The Valuation Already Full?
2026-07-15 15:13 · Yahoo
Erasca (ERAS) Surges 8.9% on Encouraging Cancer Trial Results
2026-07-14 23:40 · Yahoo
Erasca Announces Pricing of Upsized Public Offering of Common Stock
2026-07-14 03:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.